Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT to induce remission with nivolumab in checkpoint inhibitor-unresponsive melanoma
2019-004233-16Phase 4Terminated
- Sponsor
- Medical University of Graz
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of nivolumab in melanoma (2 arms), sponsored by Medical University of Graz. Primary endpoint: Progression-free survival according to iRECIST criteria. Started Mar 2021; status: terminated.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2019-004233-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004233-16.